Aytu BioPharma, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-05$2.90 RISE2026-02-13$2.13 PEAK2026-03-31$2.73 85d | -26.6% 39d | Missed | Missed | — | — | +28.2% 46d | Missed |
DROP2025-08-04$2.65 RISE2025-11-20$1.94 PEAK2026-01-05$2.90 154d | -26.8% 108d | Missed | Missed | — | — | +49.5% 46d | Missed |
DROP2025-08-04$2.65 RISE2025-09-29$1.71 PEAK2025-12-22$2.65 140d | -35.5% 56d | Missed | Missed | — | — | +55.0% 84d | Missed |
DROP2025-08-04$2.65 RISE2025-08-20$2.15 PEAK2025-09-23$2.51 50d | -18.9% 16d | Missed | Missed | — | — | +16.7% 34d | Missed |
DROP2025-01-06$1.87 RISE2025-04-14$1.00 PEAK2025-05-15$2.59 129d | -46.5% 98d | Missed | Missed | — | — | +159.0% 31d | Missed |
DROP2025-01-06$1.87 RISE2025-04-07$1.00 PEAK2025-05-15$2.59 129d | -46.5% 91d | Missed | Missed | — | — | +159.0% 38d | Missed |
DROP2024-09-26$2.85 RISE2024-12-18$1.34 PEAK2025-01-06$1.87 102d | -53.0% 83d | Missed | Missed | — | — | +39.6% 19d | Missed |
DROP2024-05-13$3.35 RISE2024-08-27$2.36 PEAK2024-09-26$2.85 136d | -29.6% 106d | Missed | Missed | — | — | +20.8% 30d | Missed |
DROP2024-04-09$3.36 RISE2024-04-15$2.68 PEAK2024-05-13$3.35 34d | -20.2% 6d | Missed | Missed | — | — | +25.0% 28d | Missed |
DROP2023-10-18$3.33 RISE2024-01-18$2.46 PEAK2024-04-09$3.36 174d | -26.1% 92d | Missed | Missed | — | — | +36.6% 82d | Missed |
DROP2023-10-18$3.33 RISE2023-11-16$2.23 PEAK2024-02-14$3.15 119d | -33.0% 29d | Missed | Missed | — | — | +41.3% 90d | Missed |
DROP2023-05-11$2.12 RISE2023-09-14$1.53 PEAK2023-10-18$3.33 160d | -27.8% 126d | Missed | Missed | — | — | +117.6% 34d | Missed |
DROP2023-04-19$2.73 RISE2023-08-08$1.64 PEAK2023-10-18$3.33 182d | -39.9% 111d | Missed | Missed | — | — | +103.0% 71d | Missed |
DROP2023-02-21$2.94 RISE2023-06-29$1.49 PEAK2023-07-14$1.87 143d | -49.3% 128d | Missed | Missed | — | — | +25.5% 15d | Missed |
DROP2023-02-21$2.94 RISE2023-06-28$1.49 PEAK2023-07-14$1.87 143d | -49.3% 127d | Missed | Missed | — | — | +25.5% 16d | Missed |
1–15 / 28 1 / 2 | |||||||
No scored news yet for a sentiment trend.
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life ...
Moby summary of Aytu BioPharma, Inc.'s Q3 2026 earnings call
Moby summary of Aytu BioPharma, Inc.'s Q3 2026 earnings call
Aytu BioPharma Inc (AYTU) reports robust initial traction for Exua despite a decline in net revenue and profit margins.
Aytu BioPharma Inc (AYTU) reports robust initial traction for Exua despite a decline in net revenue and profit margins.
Need a quote from a Motley Fool analyst? As the operator indicated, during today's call, we will be discussing Aytu BioPharma's fiscal 26 third quarter operational and financial results. Joining us on today's call is Aytu's chief executive officer, Joshua R. Disbrow and Ryan J. Selhorn, the company's chief financial officer.
Need a quote from a Motley Fool analyst? As the operator indicated, during today's call, we will be discussing Aytu BioPharma's fiscal 26 third quarter operational and financial results. Joining us on today's call is Aytu's chief executive officer, Joshua R. Disbrow and Ryan J. Selhorn, the company's chief financial officer.
Aytu BioPharma (NASDAQ:AYTU) released third-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://www.webcaster5.com/Webcast/Page/2142/53861 Summary Aytu Biopharma Inc reported a net revenue of $12.4 million for Q3 2026, down 33% year over year, impacted by a strategic shi
Aytu BioPharma (NASDAQ:AYTU) released third-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://www.webcaster5.com/Webcast/Page/2142/53861 Summary Aytu Biopharma Inc reported a net revenue of $12.4 million for Q3 2026, down 33% year over year, impacted by a strategic shi
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call May 13, 2026 4:30 PM EDTCompany ParticipantsJoshua Disbrow - CEO & DirectorRyan J.
Presentation Operator MessageOperator Good day. Welcome to the Aytu Biopharma Fiscal 2026 Q3 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn
Aytu BioPharma reports mixed Q3 results as EXXUA antidepressant launch gains early traction, with stock up 23% after hours. Revenue hit $12.4M, matching estimates.
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates Total net revenue of $12.4 million Adjusted EBITDA1 of $(2.8) million, which includes ...
Medicines Made for Life Nasdaq: AYTU May 2026 Actor portrayals. Medicines Made...
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.51) by 3.92 percent. This is a 352.38 percent decrease over earnings of $0.21 per share from
Immatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AYTU | -12.26% | -13.26% | -11.92% | +28.65% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -15.23% | -7.54% | -8.48% | +15.96% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | -0.42 | -0.41 | +2.38% |
| 2026-02-03 | -0.49 | -0.23 | +52.89% |
| 2025-11-13 | -0.19 | -0.09 | +52.10% |
| 2025-09-23 | -0.06 | -0.08 | -27.33% |
| 2025-05-14 | -0.17 | 0.21 | +223.53% |
| 2025-02-12 | -0.28 | 0.13 | +146.43% |
| 2024-11-13 | -0.34 | -0.15 | +55.88% |
| 2024-09-26 | -0.45 | -0.82 | -82.22% |
| 2024-05-15 | -0.64 | -0.52 | +18.75% |
| 2024-02-14 | -0.25 | -0.04 | +84.00% |
| 2023-11-14 | -0.04 | -1.48 | -3600.00% |
| 2023-09-27 | -0.95 | -0.59 | +37.89% |
| 2023-05-11 | -0.80 | -1.93 | -141.25% |
| 2023-02-21 | 0.20 | -1.32 | -757.95% |
| 2022-11-14 | -3.60 | -1.20 | +66.67% |
| 2022-09-27 | -7.40 | -7.00 | +5.41% |